Editor's Note

AHPA’s guidance policy on the marketing of concentrated ∆-8 tetrahydrocannabinol, artificial, or synthesized cannabinoids (adopted June 2021) acknowledges ∆-8 THC as a naturally occurring, minor constituent in hemp but discourages the marketing of goods for consumption by any route that both consist of or contain any amount of synthesized cannabinoids (including ∆-8 THC) and are labeled as hemp products. In addition, another AHPA guidance policy recommends that any product (food or supplement) derived from hemp should comply with all applicable FDA regulations. As with all AHPA guidance policies, AHPA encourages its members and non-member companies to adopt these policies to establish consistent and informed trade practices.
March 2022
FDA
The U.S. Food & Drug Administration recently released a consumer update entitled “5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC” to warn of serious health risks posed by the unregulated cannabinoid typically manufactured from hemp-derived CBD.

The following points top FDA’s list of things consumers should know to about delta-8 THC to keep themselves and those they care for safe:

1.  Delta-8 THC products have not been evaluated or approved by the FDA for safe use and may be marketed in ways that put the public health at risk.
2.  The FDA has received adverse event reports involving delta-8 THC-containing products. 
3.  Delta-8 THC has psychoactive and intoxicating effects.
4.  Delta-8 THC products often involve use of potentially harmful chemicals to create the concentrations of delta-8 THC claimed in the marketplace. 
5.  Delta-8 THC products should be kept out of the reach of children and pets.

FDA stated that their warnings about delta-8 THC are in response to an uptick in adverse event reports to the agency and national poison control centers, marketing that is appealing to children, and contamination concerns related to manufacturing. 

2022 Annual Fund Sponsors: